CADL | Candel Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	8.08 - 8.94
52 Week Range	1.1600 - 14.60
Beta	-0.85
Implied Volatility	137.81%
IV Rank	23.73%
Day's Volume	979,343
Average Volume	3,415,317
Shares Outstanding	44,475,500
Market Cap	362,697,703
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-07-27

Valuation
Profitability
Growth
Health
P/E Ratio	-4.71
Forward P/E Ratio	N/A
EPS	-1.73
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	42
Country	USA
Website	CADL

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

CADL's peers: ACXP, BRTX, BYSI, AVTE, ADAG, ACRV, RZLT, ANTX, MOLN, MLYS, PHVS, PEPG, PMVP, MNPR, ENOB, INDP, TPST, CMRA, FBRX, BNOEF, OKYO, ANEB, CINGW, CANF, INKT, KZIA, LSTA, GDTC

*Chart delayed

Analyzing fundamentals for CADL we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CADL Fundamentals page.

Watching at CADL technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CADL Technicals page.